TOPLINE:

Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical failures by more than 50% in patients with localized intermediate- or high-risk prostate cancer. The approach also significantly improved DFS, local DFS, and nodal DFS but not overall survival or distant metastasis-free survival.

METHODOLOGY:

Patients with localized intermediate- or high-risk prostate cancer often require high doses of EBRT; however, whole-gland dose escalation often leads to “unacceptable” toxicities, the researchers explained.

To address this, the FLAME trial evaluated whether adding a focal boost to tumor lesions could improve biochemical DFS. Preliminary result

See Full Page